What's Happening?
MaaT Pharma, a biotechnology company specializing in Microbiome Ecosystem Therapies, announced plans to request a re-examination of the European Medicines Agency's (EMA) negative opinion on its drug MaaT013, branded as Xervyteg, for treating acute Graft-versus-Host
Disease (aGvHD). The Committee for Medicinal Products for Human Use (CHMP) of the EMA had previously issued a negative opinion, citing insufficient data to attribute clinical effects solely to the treatment. MaaT Pharma intends to seek a Scientific Advisory Group hearing to provide further insights into the clinical management of aGvHD and the need for effective therapies.
Why It's Important?
The decision by the EMA impacts MaaT Pharma's ability to market MaaT013 in Europe, affecting patients with limited treatment options for aGvHD. The re-examination process is crucial for the company to potentially overturn the negative opinion and continue providing access to its therapy. This development highlights the challenges faced by biotech companies in navigating regulatory approvals and the importance of robust clinical data. The outcome of the re-examination could influence the company's market strategy and its ongoing efforts to expand its microbiome therapy platform.
What's Next?
MaaT Pharma will proceed with the re-examination process, which includes appointing new evaluators and potentially convening a Scientific Advisory Group. A new CHMP opinion is expected within 60 days following the re-examination request, with a decision anticipated in September 2026. The company remains confident in the clinical profile of MaaT013 and continues its Early Access Program, providing the therapy to eligible patients. The outcome of the re-examination will determine the future availability of MaaT013 in the European market and its impact on patients with aGvHD.
